Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function

E-ISSN： 2160-7648|5|3|216-224

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.5, Iss.3, 2016-05, pp. : 216-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Pharmacokinetics of Long-Acting Antipsychotic Medications

Current Clinical Pharmacology, Vol. 9, Iss. 3, 2014-08 ,pp. : 310-317

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Gepirone in Subjects with Normal Renal Function and in Patients with Chronic Renal Dysfunction

By Dogterom P.

Clinical Drug Investigation, Vol. 22, Iss. 8, 2002-08 ,pp. : 513-522

Adis International

Access to resources Recommend Favorite

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

By Jonassen Ib

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2104-2114

Springer Publishing Company

Access to resources Recommend Favorite

Stability of Two Long‐Acting Insulin Formulations after 28 Days

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 37-40

John Wiley & Sons Inc

Access to resources Recommend Favorite

An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 256-261

John Wiley & Sons Inc

Access to resources Recommend Favorite